Differential (Click to cross reference) adverse drug reaction Alzheimer's disease Alzheimer's disease, treatment of atorvastatin cerebrovascular accident cerebrovascular accident, classification cerebrovascular accident, prevention of cholesterol complications creatine phosphokinase(CPK)elevated efficacy fibrate HMGcoA reductase inhibitors hyperlipidemia interferon interferon beta 1-a lipid lowering agent multiple sclerosis multiple sclerosis, relapsing multiple sclerosis, treatment of multiple sclerosis, worsening myasthenia gravis myasthenia gravis, exacerbation myopathy myopathy, drug-induced myopathy, toxic prevention of neurologic disorders rhabdomyolysis safety SPARCL trial statin therapy transient ischemic attack treatment of neurologic disorder

Showing articles 0 to 6 of 6 Results of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Trial by Stroke Subtypes Stroke 40:1405-1409, Amarenco,P.,et al, 2009 Combining Beta Interferon and Atorvastatin May Increase Disease Activity in Multiple Sclerosis Neurol 71:1390-1395,1386, Birnbaum,G.,et al, 2008 High-Dose Atorvastatin After Stroke or Transient Ischemic Attack NEJM 355:549-559,613, The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators, 2006 Atorvastatin for the Treatment of Mild to Moderate Alzheimer Disease Arch Neurol 62:753-757, Sparks,D.L.,et al, 2005 Statin-Associated Exacerbation of Myasthenia Gravis Neurol 63:2188, Cartwright,M.S.,et al, 2004 Safety of HMG-CoA Reductase Inhibitors: Focus on Atorvastatin Cardiovasc Drugs Ther 15:211-218, Bernini,F.,et al, 2001 Showing articles 0 to 6 of 6